BBI 5000

Drug Profile

BBI 5000

Alternative Names: BBI-5000

Latest Information Update: 07 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer Brickell Biotech
  • Class Skin disorder therapies
  • Mechanism of Action Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Atopic dermatitis

Most Recent Events

  • 01 Dec 2015 Brickell Biotech completes a phase I trial in Atopic dermatitis (In volunteers) in USA (NCT02590289)
  • 03 Feb 2015 BBI 5000 licensed to Brickell Biotech for the treatment of Atopic dermatitis
  • 03 Feb 2015 Phase-I clinical trials in Atopic dermatitis (In volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top